Loading
A phase 3 trial of Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Samsung Bioepis Co., Ltd., active and no longer recruiting.
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer is a phase 3 interventional study registered as NCT06348199 by Samsung Bioepis Co., Ltd., with 555 participants enrolled, started 2024-03-12 and due to reach its primary completion in 2026-03-10. Interventions recorded: SB27, Keytruda. Conditions listed: Non-small Cell Lung Cancer Stage IV. No results are recorded here; the registry entry is the source.